Detecting intratumoral heterogeneity in routine breast-HER2 testing: Low yield of testing multiple blocks

Annals of Diagnostic Pathology

Volumn 19, Issue 6, 2015, Pages 385-390

  Bethune, Gillian C ^a,b   Mullen, J Brendan ^a,b   Chang, Martin C ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Breast pathology; HER2; Heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER SCREENING; DIAGNOSTIC VALUE; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; AGED; BREAST; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84948582243     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2015.08.001     Document Type: Article

References (25)

1. A.C. Wolff, E.H. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, and et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 144
2. A.C. Wolff, M.E. Hammond, D.G. Hicks, M. Dowsett, L.M. McShane, K.H. Allison, and et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 2013 3997 4013
3. K.H. Allison, S.M. Dintzis, and R.A. Schmidt Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity Am J Clin Pathol 136 2011 864 871
4. A.I. Bartlett, J. Starcyznski, T. Robson, A. Maclellan, F.M. Campbell, C.J. van de Velde, and et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition Am J Clin Pathol 136 2011 266 274
5. M.C. Chang, J.I. Malowany, J. Mazurkiewicz, and M. Wood 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases Mod Pathol 25 2012 683 688
6. H. Seol, H.J. Lee, Y. Choi, H.E. Lee, Y.J. Kim, J.H. Kim, and et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathol 25 2012 938 948
7. M.C. Chang Letter to the editor regarding 'Seol H, Lee HJ, Choi Y, et al. Intratumoural heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance' Mod Pathol 26 2013 609 610
8. Y. Yang, Y. Fan, R. Lang, F. Gu, M.J. Ren, X.M. Zhang, and et al. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance Breast Cancer Res Treat 134 2012 1095 1102
9. A. Fabi, A. Di Benedetto, G. Metro, L. Perracchio, C. Nisticò, F. Di Filippo, and et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care Clin Cancer Res 17 2011 2055 2064
10. M. Brunelli, E. Manfrin, G. Martignoni, K. Miller, A. Remo, D. Reghellin, and et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria Am J Clin Pathol 131 2009 678 682
11. G.H. Vance, T.S. Barry, K.J. Bloom, P.L. Fitzgibbons, D.G. Hicks, R.B. Jenkins, and et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines Arch Pathol Lab Med 133 2009 611 612
12. W.M. Hanna, J. Rüschoff, M. Bilous, R.A. Coudry, M. Dowsett, R.Y. Osamura, and et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Mod Pathol 27 2014 4 18
13. E.E. Lower, E. Glass, R. Blau, and S. Harman HER2/neu expression in primary and metastatic breast cancer Breast Cancer Res Treat 113 2009 301 306
14. H. Shafi, K. Astvatsaturyan, F. Chung, J. Mirocha, M. Schmidt, and S. Bose Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis J Clin Pathol 66 2013 649 654
15. Y. Choi, E.J. Kim, H. Seol, H.E. Lee, M.J. Jang, S.M. Kim, and et al. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/ multicentric invasive ductal carcinoma of breast Hum Pathol 43 2012 48 55
16. F. Buggi, S. Folli, A. Curcio, D. Casadei-Giunchi, A. Rocca, E. Pietri, and et al. Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Ann Oncol 23 2012 2042 2046
17. L. Hernandez, P.M. Wilkerson, M.B. Lambros, A. Campion-Flora, D.N. Rodrigues, A. Gauthier, and et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection J Pathol 227 2012 42 52
18. R.A. Burrell, N. Juul, S.R. Johnston, J.S. Reis-Filho, Z. Szallasi, and C. Swanton Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer J Cell Biochem 111 2010 782 790
19. J.J. Going, H.M. Abd El-Monem, and J.A. Craft Clonal origins of human breast cancer J Pathol 194 2001 406 412
20. P.L. Wagner, N. Kitabayashi, Y.T. Chen, and S.J. Shin Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases Am J Clin Pathol 132 2009 871 876
21. D. Ang, A.M. VanSandt, C. Beadling, A. Warrick, R.B. West, C.L. Corless, and et al. Biphasic papillary and lobular breast carcinoma with PIK3CA and IDH1 mutations Diagn Mol Pathol 21 2012 221 224
22. J.M. Harvey, G.M. Clark, C.K. Osborne, and D.C. Allred Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1999 1474 1481
23. JM Bartlett, CL Brookes, T. Robson, C.J. van de Velde, L.J. Billingham, F.M. Campbell, and et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial J Clin Oncol 29 2011 1531 1538
24. B. Bernasconi, A.M. Chiaravalli, G. Finzi, K. Milani, and M.G. Tibiletti Genetic Heterogeneity in HER2 testing may influence therapy eligibility Breast Cancer Res Treat 133 2012 161 168
25. J.T. Lewis, R.P. Ketterling, K.C. Halling, C. Reynolds, R.B. Jenkins, and D.W. Visscher Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER2 immunostaining Am J Clin Pathol 124 2005 273 281